Log in or Sign up
to access My Account functionalities
Treatment of diabetes insipidus:Dosage is individual in diabetes insipidus but the total daily sublingual dose normally lies in the range of 120 micrograms to 720 micrograms. A suitable starting dose in adults and children is 60 micrograms three times daily, administered sublingually. This dosage regimen should then be adjusted in accordance with the patient's response. For the majority of patients, the maintenance dose is 60 micrograms to 120 micrograms sublingually three times daily.
Post-hypophysectomy polyuria/polydipsia:The dose of DDAVP Melt should be controlled by measurement of urine osmolality.
Pregnancy:Data on a limited number (n=53) of exposed pregnancies in women with diabetes insipidus indicate rare cases of malformations in children treated during pregnancy. To date, no other relevant epidemiological data are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development. Caution should be exercised when prescribing to pregnant women. Blood pressure monitoring is recommended due to the increased risk of pre-eclampsia.
Lactation:Results from analyses of milk from nursing mothers receiving high dose desmopressin (300 micrograms intranasally) indicate that the amounts of desmopressin that may be transferred to the child are considerably less than the amounts required to influence diuresis.
Treatment:Although the treatment of hyponatraemia should be individualised, the following general recommendations can be given. Hyponatraemia is treated by discontinuing the desmopressin treatment, fluid restriction and symptomatic treatment if needed
|Desmopressin acetate||Desmopressin free base||Desmopressin free base||Desmopressin acetate|
|0.1mg||89 micrograms||60 micrograms||Approx. 67 micrograms +|
|0.2mg||178 micrograms||120 micrograms||Approx. 135 micrograms +|
|0.4mg||356 micrograms||240 micrograms||Approx. 270 micrograms +|